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Abstract
The tumor microenvironment represents a complex network, in which tumor cells not only communicate with each
other but also with stromal and immune cells. Current research has demonstrated the vital role of the tumor
microenvironment in supporting tumor phenotype via a sophisticated system of intercellular communication through
direct cell-to-cell contact or by classical paracrine signaling loops of cytokines or growth factors. Recently, extracellular
vesicles have emerged as an important mechanism of cellular interchange of bioactive molecules. Extracellular vesicles
isolated from tumor and stromal cells have been implicated in various steps of tumor progression, such as proliferation,
angiogenesis, metastasis, and drug resistance. Inhibition of extracellular vesicles secretion, and thus of the transfer of
oncogenic molecules, holds promise for preventing tumor growth and drug resistance. This review focuses on the role
of extracellular vesicles in modulating the tumor microenvironment by addressing different aspects of the bidirectional
interactions among tumor and tumor-associated cells. The contribution of extracellular vesicles to drug resistance will
also be discussed as well as therapeutic strategies targeting extracellular vesicles production for the treatment of cancer.
Keywords: Tumor microenvironment, Stroma, Metastasis, Extracellular vesicles, Drug resistance
Background
The last decades have revealed that the malignant prop-
erties and progression of tumors are not controlled by
cancer cells exclusively [1]. The area surrounding the
tumor contains various non-malignant cell types, includ-
ing fibroblasts, lymphocytes, inflammatory cells, endo-
thelial cells, adipose tissue, and mesenchymal stem cells
[1]. In the early stages of tumorigenesis, the microenvir-
onment displays anti-tumor immunity and controls
tumor growth [2]. As the tumor continues to develop,
the role of the microenvironment shifts over to be
tumor promotive [2]. Cells found in the tumor micro-
environment (TME) have been recognized as key regula-
tors of tumor promotion by providing mitogenic growth
factors, growth inhibitory signals or trophic factors [2].
The complex heterotypic interactions between tumor
cells and non-cancerous cells within the TME occur
through direct contact between cells or paracrine signal
exchange of cytokines and growth factors [2]. The most
well-recognized cell-to-cell interaction within the TME
is between tumor cells and macrophages or fibroblasts
[2]. Macrophages play an integral role in host innate im-
mune response against infections [3]. Tumor cells
release factors, such as vascular endothelial growth fac-
tor (VEGF), colony stimulating factor 1 (CSF1), and
platelet-derived growth factor (PDGF), that aid in the re-
cruitment of macrophages to tumors [3]. Once the mac-
rophages are recruited to the tumor, they can promote
tumor progression by enhancing tumor cell proliferation,
as well as by remodeling the tumor stroma to facilitate
invasion and angiogenesis [3]. Fibroblasts are responsible
for the production of extracellular matrix (ECM), such
as collagen and fibronectin, and facilitate remodeling in
wound healing [4]. Cancer-associated fibroblasts (CAFs)
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support tumor growth, invasion, metastasis and induce
inflammation [4]. Stromal cell-derived factor 1 (SDF1) is
a CAF-secreted factor that can activate C-X-C chemo-
kine receptor type 4 (CXCR4) and ultimately stimulates
cancer cell proliferation [2, 4]. CAF-derived transform-
ing growth factor-beta (TGF-β) promotes the metastatic
potential of tumor cells by driving an epithelial-to-mes-
enchymal transition (EMT) [2, 4].
Recently, it has become apparent that secreted extra-
cellular vesicles (EVs) are proficient intercellular com-
munication mediators [2]. EVs are a heterogeneous
population of cell-derived membrane vesicles that are
secreted by various cell types. They exhibit a wide size
range and differ by their biogenesis. EVs include exo-
somes, which are small membrane vesicles, ranging from
30 to 150 nm in diameter, and shed microvesicles (MVs),
which are large membrane vesicles of 150 to 1000 nm
diameter budding off the plasma membrane [5]. Smaller
shed MVs have also been reported, which are ~ 100 nm
in diameter [6]. Oncosomes are even larger EVs that are
also shed off from the plasma membrane and are 1 to
10 μm in diameter [7]. EVs contain a diverse array of
bioactive cargoes, including proteins, lipids, and nucleic
acid [5, 7, 8]. The lipid bilayer of EVs encapsulates their
contents, shielding them from enzymatic degradation
[2]. EVs regulate multiple cellular processes including
cell proliferation, survival, and transformation through
autocrine and paracrine interactions [5, 8].
Multiple mechanisms are involved in the biogenesis
of EVs: exosomes originate as intraluminal vesicles
(ILVs) via inward budding of the limiting membrane of
maturing endosomes, giving rise to multivesicular
endosomes (MVEs) [5]. MVEs are prone to fuse with
lysosomes for degradation of their contents, however,
they can also dock and fuse with the plasma membrane
to release ILVs into the extracellular space [5]. One of
the best-characterized mechanism of exosome biogen-
esis involves the recruitment of the endosomal sorting
complex required for transport (ESCRT) machinery to
ubiquitinated proteins in the early endosome. There are
four ESCRT complexes (ESCRT-0, −I, −II, and -III),
which associate with ESCRT-associated accessory pro-
teins, such as the ATPase VPS4, its cofactor VTA-1,
TSG101, and Alix. ESCRT-0 complex recognizes and
sequesters ubiquitinated proteins on the outside of the
endosomal membrane. ESCRT-I and –II complexes are
responsible for starting and driving intraluminal mem-
brane budding. ESCRT-III complex performs vesicle
scission to form MVEs [9]. Trajkovic et al. have also
described an ESCRT-independent exosome biogenesis
pathway, which is mediated by the sphingolipid
ceramide [10]. Ceramide is produced from the hydroly-
sis of sphingomyelin by neutral sphingomyelinase 2
(nSMase2) [10]. The cone-shaped structure of ceramide
stimulates the negative membrane curvature to facilitate
the membrane invagination of ILVs [10]. The authors re-
ported that nSMase2 is needed for the release of proteo-
lipid protein (PLP) from Oli-neu cells [10]. In addition,
the ceramide-mediated exosome biogenesis pathway ap-
pears to be important for microRNA (miRNA) export
via exosomes [11]. Tetraspanin CD63 has also been
shown to be involved in the sorting of melanocyte pro-
tein PMEL into exosomes in an ESCRT-independent
mechanism [12]. Some of the key regulators of MVE
docking and fusion with the plasma membrane include
several Rab family members (Rab11, Rab35, Rab27) as
well as synaptotagmin-7 [13–17]. It was previously re-
ported that cortactin and Rab27a coordinate to stabilize
branched actin networks to allow MVE docking near
the plasma membrane and exosome secretion at invado-
podia [18].
MVs are formed by the outward budding, fission of
the plasma membrane, and release into the extracellular
space [5, 7]. The biogenesis of MVs is distinct from that
of MVEs-derived exosomes [5, 7]. During MVs gener-
ation, there are molecular rearrangements at the sites of
MVs budding resulting in an alteration of the lipid and
protein compositions of the plasma membrane [5, 7].
One of the mechanisms of the MVs formation involves
phospholipid reorganization by aminophospholipid
translocases (floppases and flippases) [5, 7]. The trans-
location of phosphatidylserine (PS) from the inner leaflet
to the outer leaflet by floppase induces the budding and
release of MVs [5, 7]. Another contributor to MVs bud-
ding is the small GTPase protein, ADP-ribosylation fac-
tor 6 (ARF6). ARF6 stimulates phospholipase D (PLD),
which subsequently leads to the association of extracel-
lular signal-regulated kinase (ERK) with the plasma
membrane [19]. ERK is responsible for the phosphoryl-
ation of myosin light-chain kinase (MLCK) [19]. Acti-
vated MLCK promotes the phosphorylation and the
activation of the myosin light chain. The end result of
this signaling cascade is the contraction of actomyosin at
the “necks” of MVs, which facilitates MVs release [19].
Another mechanism of MVs formation is mediated by
Arrestin 1 domain-containing protein 1 (ARRDC1).
Nabhan et al. reported that ESCRT-I subunit TSG101 is
recruited to the plasma membrane through its inter-
action with ARRDC1, which is dependent on a con-
served PSAP motif in ARRDC1 [6]. The budding of
ARRDC1-mediated microvesicles (ARMMs) needs both
TSG101 and the ESCRT-associated ATPase VSP4 [6].
The association of ARRDC1 with ubiquitin ligase WWP2
subsequently leads to the ubiquitination of ARRDC1 and
drives the budding of ARMMs [6]. One characteristic of
ARMMs is that they differ from other MVs in their size.
ARMMs are ~ 100 nm in diameter, which is similar to the
size of exosomes [6]. Wang et al. recently reported that a
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functional NOTCH2 receptor is released via ARMMs.
Once the NOTCH2-containing ARMMs are transferred
to recipient cells, the expression of NOTCH2 target genes
(HES1 and HES5) was induced [20].
It is now clear that EVs serve as vehicles for bidirec-
tional communication between cells. The receptors and
ligands found on the outside of EVs provide a vectorial
cargo transfer to cells expressing the cognate ligand/re-
ceptors, conferring specificity to this interaction [8, 12].
There are multiple processes by which EVs and their
cargoes can be transferred to recipient cells. EVs may
anchor at the plasma membrane of a target cell [21, 22].
Bound EVs may fuse directly with the plasma membrane
of the recipient cell [21, 22]. Additionally, bound EVs
can be taken up by phagocytosis, macropinocytosis, lipid
raft-mediated endocytosis, clathrin-mediated endocyto-
sis, or caveolin-mediated endocytosis [21, 22]. When
endocytosed, EVs can be targeted to lysosomes for deg-
radation [21, 22]. An alternative fate is that EVs could
fuse with the delimiting membrane of an endocytic
compartment, which subsequently allows for the re-
lease of EV content into the cytosol of the recipient
cells [21, 22]. EVs carry bioactive molecular cargoes,
including various proteins, lipids and nucleic acids
(DNA, mRNA fragments, miRNA, small nucleolar RNA,
Y RNA, mitochondrial RNA, and other non-coding
RNAs) that can affect the functions and phenotypes of
recipient cells by altering gene expression via de-novo
translation and/or post-translational modifications of tar-
get mRNAs [5, 8] or by activating various signaling path-
ways [8, 22].
Given the lack of standardized nomenclature and iso-
lation protocols for extracellular vesicles, we will com-
monly refer to exosomes, microvesicles, oncosomes, or
microparticles as extracellular vesicles.
Extracellular vesicles as modulators of the tumor
microenvironment
A critical biological feature that contributes significantly
to cancer progression, invasion and metastasis is the
‘tumor microenvironment’ [23]. The tumor microenvir-
onment (TME) is an interactive cellular environment
surrounding the tumor whose main function is to estab-
lish cellular communication pathways supporting tumori-
genesis [24]. The cellular component of the TME mainly
comprises immune and inflammatory cells, stromal fibro-
blasts, and endothelial cells forming the blood vessels that
secrete a series of extracellular/angiogenesis signaling
molecules, which in turn lead to a functional modulation
of TME [23]. The TME then converts into a pathological
entity that continually evolves to aid cancer progression
and invasion [24]. The extracellular vesicles (EVs) secreted
by tumors, commonly known as tumor-derived EVs,
have been well documented to modulate the tumor
microenvironment (Fig. 1) [25]. EVs are highly special-
ized entities of communication carrying several surface
markers and signaling molecules, oncogenic proteins
and nucleic acids that can be transferred horizontally to
the stromal target cells and condition the tumor micro-
environment for an improved tumor growth, invasion,
and metastasis [26–28]. The role of EVs in cancer pro-
gression and metastasis is described in detail below.
Extracellular vesicles and stromal activation
Stromal cells, together with extracellular matrix compo-
nents are critical components of the tumor microenvir-
onment, playing crucial roles in tumor initiation,
progression, and metastasis [29]. One of the main stro-
mal changes within the TME is the appearance of
cancer-associated fibroblasts (CAFs) [29]. CAFs consti-
tute a major portion of the reactive tumor stroma and
play a crucial role in tumor progression. Tumor-derived
EVs are essential mediators of the intercommunication
between tumor and stromal cells, contributing to stro-
mal support of tumor growth. Tumor-associated EVs
have been reported to play a significant role in the
differentiation of fibroblasts into CAFs, inducing a
tumor-promoting stroma [30]. In addition to fibroblasts
activation, tumor-derived EVs can also induce the differ-
entiation of mesenchymal stem cells, and other bone
marrow-derived cells to become tumor-supportive cells
by delivering growth factors, such as transforming
growth factor-beta (TGF-β) and various miRNAs [1, 31].
For instance, breast cancer and glioma cells are capable
of conferring cancer transformed characteristics to nor-
mal fibroblasts and epithelial cells through the transfer
of cancer cell-derived EVs carrying the cross-linking en-
zyme tissue transglutaminase (tTG)-crosslinked fibro-
nectin [32]. More recently, it was reported that ovarian
cancer cells secrete EVs capable of modulating fibro-
blasts behavior towards a CAF-like state. The secretome
of the CAFs is, in turn, able to promote the proliferation,
motility, and invasion of the tumor and endothelial cells
[33]. Furthermore, in a prostate cancer cell model, the
release of TGF-β1-associated EVs triggers fibroblast
differentiation into a myofibroblast phenotype support-
ing angiogenesis in vitro and accelerating tumor growth
in vivo [34]. Likewise, EVs derived from osteosarcoma
cells carry a high level of surface-associated TGF-β1,
which induces mesenchymal stem cells to secrete
interleukin-6 and is associated with increased metastatic
dissemination [35]. Breast cancer cells-derived EVs have
also been reported to promote the acquisition of
myofibroblast-like features in mesenchymal stem cells
derived from adipose tissue [36]. Moreover, colorectal
cancer-derived EVs were able to induce a tumor-like be-
havior in mesenchymal stromal cells, suggesting that the
inflammatory microenvironment initiated by cancer
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cells-derived EVs promotes tumor growth and invasive-
ness [37]. Another mechanism described in
tumor-stromal remodeling via EVs is the transfer of
non-coding oncogenic miRNAs. Indeed, transfer of the
pro-metastatic miRNA, miR-9, in breast cancer-derived
EVs enhanced the switch of human breast fibroblasts to
CAFs, resulting in enhanced cell motility [38]. Conse-
quently, CAF-derived EVs may, in turn, support tumor
growth, survival, invasion, and metastasis. For instance,
CAF-derived EVs have been reported to increase the ex-
pression of Snail in recipient pancreatic ductal adenocar-
cinoma cells and thus to promote proliferation and drug
resistance [39]. It has also been shown that fibroblasts se-
crete EVs that promote breast cancer cells protrusive ac-
tivity, motility, and metastasis by activating autocrine
Wnt-planar cell polarity (PCP) signaling [40]. Moreover,
breast cancer cells exposed to CAF-derived EVs carrying
miRs − 21, −378e, and − 143 display significantly increased
stemness and EMT phenotypes [41].
Extracellular vesicles and angiogenesis
Angiogenesis is the process of new blood vessels forma-
tion from pre-existing vessels occurring in physiological
conditions such as growth or in response to tissue in-
jury. In healthy tissues, angiogenesis is tightly regulated
by a precise balance between stimulatory and inhibitory
angiogenic signals controlling the proliferation and
migration of endothelial cells. An imbalance in this regu-
latory network may cause several diseases, such as can-
cer. In the past decade, EVs secreted by different cells
within the tumor microenvironment have been shown to
be important mediators of pathological angiogenesis
through the release of angiogenic factors that can be
transferred to endothelial cells, thus leading to the gen-
eration of a pro-angiogenic niche that supports tumor
growth [42]. Indeed, EVs produced by human lung or
colorectal cancer cells transfer oncogenic EGFR to cul-
tured endothelial cells, in which they elicit EGFR-
dependent responses, including activation of MAPK and
Fig. 1 Role of the extracellular vesicles-mediated intercommunication in tumor development and progression. Tumor and stromal cells release
extracellular vesicles as a mean of communication contributing to the complexity and heterogeneity of the tumor microenvironment.
Extracellular vesicles-mediated transport of bioactive materials can induce a tumor microenvironment favorable for tumor growth and resistance
to anti-cancer drugs
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AKT pathways, as well as an autocrine production and
signaling of VEGF [43]. It was also reported that upregu-
lation of heparanase in myeloma and breast cancer cells
is associated with increased release of Syndecan-1,
Vascular Endothelial Growth Factor (VEGF), and
Hepatocyte Growth Factor (HGF) in EVs, leading to in-
creased endothelial invasion through the ECM [44]. Fur-
thermore, hypoxic glioblastoma cells have been shown
to induce the secretion of high amounts of tissue factor
(TF)-associated EVs that trigger a paracrine activation of
endothelial cells through a PAR-2-mediated heparin-
binding EGF signaling [45]. Interestingly, a study con-
ducted by Kucharzewska and colleagues has shown that
endothelial cells were programmed by glioblastoma
cell-derived hypoxic EVs to secrete several potent
growth factors and cytokines and to stimulate pericyte
PI3K/AKT signaling activation and migration. Using an
in vivo glioblastoma mouse xenograft model, the authors
found that hypoxic EVs significantly enhanced tumor
vascularization, pericyte vessel coverage, and glioblast-
oma cell proliferation [46]. Also, hypoxic colorectal can-
cer cells have been shown to secrete Wnt4-enriched EVs
that promote beta-catenin (β-catenin) nuclear transloca-
tion and proliferation of endothelial cells [47]. Tumor
EVs have also been reported to modulate angiogenesis in
tumors via the release of non-coding RNAs. For ex-
ample, miR-9 contained in EVs promotes tumor angio-
genesis and endothelial cells migration through the
reduction of suppressor of cytokine signaling 5 (SOCS5)
levels and the activation of the JAK/STAT pathway [48],
while EVs carrying miR-23a are capable of inducing
angiogenesis in different angiogenic model systems by
targeting SIRT1 in recipient endothelial cells [49]. Like-
wise, neutral sphingomyelinase 2 (nSMase2) (an enzyme
that generates ceramide) promotes angiogenesis in endo-
thelial cells through the transfer of pro-angiogenic EVs
enriched for miR-210 [50].
Extracellular vesicles and immune escape
The tumor microenvironment is infiltrated by a variety
of immune cells, such as lymphocytes (T cells, B cells,
natural killer cells, and T regulatory cells), dendritic
cells, monocytes, macrophages, myeloid-derived sup-
pressor cells (MDSC), and granulocytes (neutrophils,
basophils, eosinophils, and mast cells). The main role of
these cells is to assure immune surveillance. However,
tumor cells have been recognized to be capable of
modulating signaling pathways within these immune
cells and converting them into an immunosuppressive
entity, thus leading to enhanced cancer cell survival and
proliferation [51]. Despite the fact that EVs contain
tumor antigens capable of priming an anti-tumor im-
mune response, accumulating evidence demonstrates
that tumor cells utilize EVs in order to suppress the
anti-tumor response through the secretion of bioactive
immunosuppressive molecules. Actually, EVs have been
shown to be critical mediators of the immune-cancer
cell communication. One example of how tumor-derived
EVs aid in evading immune surveillance is by inducing
apoptosis in immune cells. Indeed, several tumor-de-
rived EVs have been shown to be enriched for Fas ligand
(Fas-L) which induces cell apoptosis when binding to its
receptor. Wieckowski et al. described that Fas-L-positive
tumor-derived EVs induce immune suppression by pro-
moting the expansion of T regulatory cells and the apop-
tosis of anti-tumor CD8(+) effector T cells, thus
contributing to immune escape [52]. Similarly, this im-
mune suppression mechanism through the release of
Fas-L-containing EVs capable of inducing T-cell apop-
tosis was also reported in several cancer models, such as
head and neck squamous cell carcinoma, melanoma,
prostate, and colorectal cancer [53–56]. The presence of
other mediators of T- cell apoptosis in tumor-derived
EVs has been reported for galectin-1 and -9, both caus-
ing T-cell apoptosis and immune suppression [57, 58].
Similarly, EVs released from mesothelioma, acute mye-
loid leukemia, or colorectal cancer have been shown to
contain the transforming growth factor (TGF-β) on their
surface and to deliver it to T-cells, inhibiting their prolif-
eration in response to interleukin-2 and changing their
phenotype to regulatory T cells [59–61]. Moreover,
tumor-released EVs have been shown to impair mono-
cyte differentiation into dendritic cells and to promote
the generation of a TGF-β secreting myeloid immuno-
suppressive cell subset (MDSC), which inhibit T
lymphocyte proliferation [62]. The enrichment of prosta-
glandin E2 (PGE2) and TGF-β in tumor-derived EVs in-
duces the accumulation of MDSCs with immune
suppressive properties [63]. Similarly, it has been shown
that tumor-derived EV-associated Hsp72 or Hsp70 me-
diate the suppressive activity of the MDSCs via STAT3
activation [64, 65]. The presence of HSP72 and HSP105
in EVs has also been reported in melanoma, lung, and
breast cancer cell lines, as well as in the serum of breast
cancer patients. These EVs have been shown to activate
dendritic cells and induce secretion of interleukin-6,
which promotes tumor invasion by increasing MMP-9
metalloproteinase expression [66]. Tumor cells can also
release EVs containing MHC class 1 related chain ligand
A (MICA) that is capable of binding to the NK cells re-
ceptor, NKG2D, leading to its downregulation and
resulting in a marked reduction in NK cytotoxicity inde-
pendent of NKG2D ligand expression by the target cell
[67]. Tumor-released miRNAs have also been involved
in immune suppression. For instance, miR-214 secreted
into EVs from Lewis Lung carcinoma cells was suffi-
ciently delivered into recipient T cells and in vivo studies
indicated that miR-214 mediates regulatory T cell
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expansion resulting in enhanced immune suppression
and tumor growth in mice [68].
Extracellular vesicles and metastasis
Metastasis is a multistep process leading to the dissem-
ination of primary tumor cells to distant organs. Tumor-
derived EVs have almost been involved in all steps of
tumor invasion and metastasis [15, 69–71]. Studies have
reported that tumor-associated EVs play a significant
role in invasion and metastasis through invadopodia for-
mation [18, 72]. Invadopodia are dynamic actin-rich
membrane protrusions that tumor cells produce to de-
grade and invade through the extracellular matrix [72].
It was recently proposed that invadopodia are docking
sites for EVs facilitating the degradation of the extracellu-
lar matrix through a localized secretion of metalloprotein-
ase MT-1-MMP, thus promoting cell invasion [15, 73].
Similarly, the migration of tumor cells through tissues and
chemotactic gradients is also initiated by the formation
and release of fibronectin-bound EVs at the leading edge
of migrating cells. These fibronectin-bound EVs are pro-
posed to promote adhesion assembly and stabilization
allowing a directional and persistent tumor cell migration
[74, 75]. Tumor-derived EVs are also known to influence
the integrity of vascular barriers, which is frequently asso-
ciated with metastatic dissemination. Proteomics analysis
of tumor-associated EVs has shown that EVs release a
number of proteins such as SERPINA1, SERPINF2, and
MMP9, the up-regulation of which play a significant
role in ECM remodeling, vascular leakiness, and inva-
siveness [76]. Likewise, melanoma-derived EVs have
been shown to induce pulmonary vascular leakiness
[77], while EVs produced by glioblastoma cells contain-
ing high levels of VEGF-A induce endothelial cell per-
meability and angiogenesis in vitro [78]. In addition,
EVs derived from lung cancer or breast cancer cells
were reported to carry miR-23a and miR-105 respect-
ively, which both target tight junction protein ZO-1,
thereby increasing vascular permeability and cancer
transendothelial migration [79, 80]. An interesting fea-
ture of tumor-derived EVs is their ability to establish a
pre-metastatic niche, a phenomenon where the primary
tumor can promote its own metastasis by recruiting
stromal cells to distant organs or by modulating gene
expression of distant cells in order to establish a growth
supportive environment. EVs derived from colorectal
cancer cells enriched for miR-21 can be specifically tar-
geted to liver tissue and induce liver macrophage
polarization towards an interleukin-6 (IL-6)-secreting
pro-inflammatory phenotype, therefore promoting an
inflammatory pre-metastatic niche supportive of liver
metastasis [81]. Moreover, melanoma EVs were shown
to home to lymph nodes and consequently enhance the
migration of melanoma cells to sentinel lymph nodes.
In addition, melanoma EVs were able to upregulate the ex-
pression of genes within the distal lymph node micro-
environment related to tumor cell recruitment to sentinel
nodes, extracellular matrix modifiers promoting trapping
of melanoma cells, and vascular growth factors promoting
melanoma growth, creating a pre-metastatic niche sup-
portive of metastasis [82]. Melanoma-derived EVs were
further reported to educate bone marrow-derived cells to-
wards a pro-vasculogenic and pro-metastatic phenotype
through the receptor tyrosine kinase MET [77]. More
recently, the uptake of pancreatic ductal adenocarcinoma-
derived EVs by Kupffer cells (liver macrophages) was
reported to cause TGF-β secretion and upregulation of fi-
bronectin production by hepatic stellate cells, leading to
an enhanced recruitment of bone marrow-derived macro-
phages through macrophage migration inhibitory factor
(MIF), whose association with EVs correlated with liver
metastasis occurrence and disease progression [83]. Inter-
estingly, using different tumor models, Hoshino and col-
leagues reported that the metastatic organotropism and
establishment of a pre-metastatic niche is mediated by
EVs via the secretion of different sets of integrins (for e.g.
integrin- α6β4, α6β1, or αvβ5) that favor the preferential
fusion of tumor cells with resident cells at their predicted
destination. The authors showed that tumor-derived
EVs taken-up by organ-specific cells prepared the
pre-metastatic niche and that distinct integrin patterns
predicted the organotropism of tumor cells, integrins
α6β4, and α6β1 being associated with lung metastasis,
while integrin αvβ5 was found to be associated with
liver metastasis [84]. Reprogrammed glucose metabol-
ism is a hallmark of cancer cells. Remarkably, cancer
cells are also proficient in reprograming the glucose
metabolism of stromal cells through the release of EVs
carrying high levels of the miR-122 that target the
glycolytic enzyme pyruvate kinase. This mechanism is
proposed to facilitate metastasis by increasing nutrient
availability in the pre-metastatic niche [70].
Extracellular vesicles as modulators of anti-cancer
drug resistance
Drug resistance poses a serious challenge for the treat-
ment of cancer and occurs when cancer cells become
tolerant to anti-cancer drugs. Although many types of
cancers are initially susceptible to anti-cancer drugs,
tumor cells can develop resistance over time through
different mechanisms that impair drug efficacy. The
most common mechanisms of drug resistance include
genetic or epigenetic upregulation of prosurvival signal-
ing and inhibition of apoptotic pathways, drug inactiva-
tion or alteration of drug target molecules,
overexpression of multidrug resistance proteins (MDR)
and increased transport of efflux pumps, or drug export.
Recently, the emergence of EVs as novel drug resistance
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modulators has added to the complexity of resistance
mechanisms. EVs mediate intercellular communication
by transferring proteins and nucleic acids to remote tar-
get cells. The development of drug resistance via EVs is
articulated around mechanisms involving such cargo.
EVs can mediate drug resistance by directly exporting or
sequestering cytotoxic drugs, reducing their effective
concentration at target sites. Recent evidence has shown
that EVs play an important role not only in mediating
drug resistance, but also in conferring resistance to
drug-sensitive cancer cells. Indeed, EVs are capable of
horizontal transfer of specific bioactive cargoes that may
alter cell cycle control and apoptotic programs in recipi-
ent cells (Fig. 2). EVs can also mediate intercommunica-
tion between cancer cells and stromal cells within the
tumor microenvironment, leading to the acquisition of
drug resistance and tumor progression. Mastering our
understanding of these resistance mechanisms will help
in improving cancer treatments and subsequently
patients’ outcome. Detailed mechanisms by which resist-
ance may occur are outlined in this section.
Extracellular vesicles as a sink for immunotherapies
Cancer cells use extracellular vesicles to compromise
targeted therapies. EVs carry on their surface, a plethora
of cellular antigens displayed in an orientation identical
to that found on the surface of cells from which they
emanate. The presence, on EVs surface, of cellular anti-
gens targeted by immunotherapy acts as a sink for
monoclonal antibodies-based drugs, thereby diminishing
their bioavailability to their intended target. In the case
of B-cell lymphoma, the presence of CD20 on the sur-
face of EVs protects targeted lymphoma cells from ritux-
imab (an anti-CD20 monoclonal antibody) attack [85].
In vitro as well as in vivo studies in breast cancer point
to the role of HER2-positive extracellular vesicles in
modulating resistance to anti-HER2 monoclonal anti-
body Trastuzumab. Extracellular vesicles secreted either
Fig. 2 Mechanisms of extracellular vesicles-mediated transfer of anti-cancer drug resistance. Extracellular vesicles can mediate drug resistance by
directly exporting or sequestering cytotoxic drugs reducing their effective concentration at target sites. Extracellular vesicles can also compete
with bona fide target cells for the binding of immunotherapeutic agents targeting cellular antigens. Extracellular vesicles also mediate transfer of
drug resistance to drug-sensitive cancer cells through the horizontal transfer of specific bioactive cargoes including drug efflux pumps, prosurvival
factors, inhibitors of apoptosis, and non-coding RNAs
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by HER2-positive tumor cells in vitro or found in the
serum of breast cancer patients bind to Trastuzumab,
and inhibit its activity in vitro [86]. More recently, EVs
have been involved in another type of drug resistance
mediated by cellular receptor expression. The immuno-
therapy breakthrough crowned by the 2018 Medicine
Nobel prize consists in the use of inhibitors of immune-
checkpoints to unleash the power of an immune system
otherwise tamed by immune checkpoint ligand expressed
on the surface of tumor cells. The disruption of the inter-
action of the checkpoint ligand (e.g. PD-L1) with the in-
hibitory checkpoint receptor (PD-1) on T cells, restores T
cell function and anti-tumor immunity. However, not all
patients respond to such immune checkpoint inhibitor
therapy, and the presence of checkpoint ligand (PD-L1)
on EVs early after therapy, classifies patients as responders
or resistant to anti-PD-1 therapy in melanoma [87]. By
capturing the immunotherapeutic antibody on their sur-
face, EVs drive this antibody away from the tumor, leaving
it free to engage PD-1 on oncoming tumor-specific T cells.
The same mechanism has been described in the case of
glioblastoma in vitro, in which tumor-derived EVs were
shown to express PD-L1 and inhibit T cell proliferation as
well as antigen-specific T cell responses [88].
Extracellular vesicles-mediated drug export and
sequestration
Irrespective of the administration route of anti-cancer
drugs, systemic, oral or subcutaneous, the main goal of
the treatment is to target drugs to the tumor site, where
cellular drug uptake or membrane permeability are de-
terminant in the drug efficacy and treatment success.
However, it is recognized that abnormal tumor architec-
ture (e.g.: poor vascularization, abnormal extracellular
matrix) complicates drug uptake and is associated with
therapy failure and drug resistance [89]. Even in case of
efficient uptake of drugs by targeted cells, cancer cells
are known to export drugs in the extracellular space
using specialized transporters of the multi-drug resist-
ance (MDR)-ATP binding-cassette (ABC transporters)
system [90]. These pumps reduce the intracellular accu-
mulation of many anti-cancer drugs to sub-therapeutic
levels, thus decreasing or abolishing drug efficacy. In
addition, EVs can be utilized by cancer cells as drug ve-
hicles to facilitate drug resistance through drug seques-
tration and expulsion. Shedden and colleagues were the
first to report a positive correlation between the expres-
sion of genes associated with vesicle shedding and drug
resistance in a large panel of different cancer cell lines
[91]. Furthermore, using a breast cancer cell line, they
showed by fluorescence microscopy and flow cytometry
that the fluorescent chemotherapeutic agent doxorubicin
was physically encapsulated into vesicles and expelled
out into the extracellular media [91]. More recently,
melanoma cells were shown to resist to cisplatin treat-
ment through an extracellular acidification-mediated in-
crease of EVs secretion and the direct export of cisplatin
into these vesicles [92]. Similarly, cisplatin was found to
be disposed out of resistant ovarian carcinoma cells in
extracellular vesicles [93]. Interestingly, EVs from resistant
cells not only contained Multidrug Resistance-associated
Protein 2 (MRP-2) but also the copper-transporting
P-type ATPases, ATP7A and ATP7B [93]. B-cell lymph-
oma cells also efficiently extruded doxorubicin and pixan-
trone in EVs in vitro [94]. Interestingly, ATP-transporter
A3 (ABCA3) expression is crucial for EVs biogenesis and
contributes to the observed drug resistance. Indeed, gen-
etic or chemical depletion of ABCA3 enhanced intracellu-
lar retention of both drugs [94].
Cancer cells can also sequester drugs within intracellu-
lar vesicles preventing them from reaching the targeted
subcellular compartment and rendering them nonfunc-
tional. In a breast cancer cell model resistant to mitox-
antrone, cells displayed increased EV-like structures at
the plasma membrane containing the ATP-binding cas-
sette ABCG2 in which mitoxantrone was significantly
sequestered [95]. Subcellular drug sequestration was also
shown to be mediated by ABCA3 in leukemia cells re-
sistant to a panel of cytostatic drugs [96]. Indeed,
ABCA3 localized to the limiting membranes of lyso-
somes and multivesicular bodies and caused cytostatic
drugs to be efficiently sequestered [96].
Extracellular vesicles-mediated transfer of drug efflux
pumps
In addition to drug export or sequestration, cancer cells
can transmit resistance through horizontal transfer of EVs
carrying drug efflux pumps. Drug efflux transporters of
the multi-drug resistance (MDR)-ATP binding-cassette
(ABC transporters) system have long been acknowledged
as major contributors to multidrug resistance in tumor
cells [90]. EVs carrying P-glycoprotein (P-gp, MDR-1 or
ABCB1), one of the most well-studied drug efflux pump,
have been implicated in the transfer of multidrug resist-
ance to sensitive cells in several human cancer models,
such as prostate and ovarian cancers, acute T lympho-
blastic leukemia, and osteosarcoma [97–100]. Indeed, EVs
from sera of patients undergoing a course of docetaxel
treatment compared to matched EVs from the same pa-
tients prior to commencing docetaxel treatment, when ap-
plied to both prostate cancer drug sensitive and resistant
cells, showed a correlation between cellular response to
docetaxel and patients’ response to treatment with doce-
taxel [97]. Similarly, extracellular vesicles-mediated inter-
cellular transfer of functional MRP1 drug efflux
transporter (ABCC1) was reported in leukemia cells [101].
Other drug efflux exporters such as ABCG2 or ABCA3
have been shown to transfer horizontally through EVs and
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modulate drug resistance in recipient cells [85, 102]. Al-
though tumor cells represent an abundant source of EVs,
it is important to question whether the consequences of
this transfer of cargo is sustainable in vivo. The presence
of selective P-gp/MDR-1 mRNA in EVs released from
doxorubicin-resistant osteosarcoma cells suggests that re-
sistant tumor cells use several means to spread drug resist-
ance to sensitive cells, either by transferring MDR
proteins directly to sensitive cells or by transferring the
mRNA that encodes them, contributing to the diversity of
drug resistance mechanisms [100]. On the other hand, de-
pletion of drug efflux pumps through EVs exocytosis has
been shown to increase the sensitivity of tumor cells to
anti-cancer drugs in vitro. In an in vivo setting, one can le-
gitimately wonder whether this in vitro beneficial response
could not result in a net drug resistance within the tumor
microenvironment. Indeed, these EVs loaded with MDR
transporters could be transferred to other cells within the
heterogeneous tumor itself or the stromal cells within the
tumor microenvironment, therefore possibly influencing
their response to treatment.
Extracellular vesicles-mediated export of prosurvival cargo
EVs transfer of cargo can contribute to the heterogeneity
of tumor response to anti-cancer drugs. This cargo in-
cludes prosurvival factors, which enhance cell viability
and decrease apoptosis sensitivity, thus leading to resist-
ance to anti-cancer drugs. For instance, components as-
sociated with the PI3K/AKT pathway, one of the major
oncogenic signaling axis involved in cancer cell prolifer-
ation and survival, have been reported in EVs. In hepato-
cellular carcinoma (HCC) invasive cells lines, resistance to
Sorafenib in vitro as well as in vivo was induced by deliv-
ery of hepatocyte growth factor (HGF) through EVs and
subsequent activation of the HGF/c-MET/PI3K/AKT sig-
naling pathway [103]. In addition, platelet-derived growth
factor receptor-beta (PDGFR-β), which is enriched in EVs
released by melanoma cells resistant to BRAF inhibitor,
PLX4720, can be transferred to recipient melanoma cells,
resulting in a dose-dependent activation of PI3K/AKT sig-
naling and escape from BRAF inhibition [104]. More re-
cently, triple negative breast cancer cell lines resistant to
Docetaxel and Doxorubicin were shown to release EVs
that induced resistance to these chemotherapy drugs in re-
cipient non-tumorigenic breast cells [105]. Indeed, these
EVs caused changes in gene expression associated with cell
proliferation and apoptosis including the PI3K/AKT path-
way, suggesting that they may contain ligands or receptors
connected to the PI3K signaling axis [105]. Likewise, EVs
can also carry prosurvival molecules that modulate the
immune system functions likely inducing immune toler-
ance and escape. Transforming growth factor-β (TGF-β)
cytokines have been shown to play a critical role in estab-
lishing immunological suppression [106]. Indeed, TGF-β1
was found in tumor-derived EVs and reported to inhibit
the proliferation of healthy donor peripheral blood lym-
phocytes in response to IL-2 and to induce regulatory T
cells [59]. Additionally, in vivo and in vitro studies on
HER2-overexpressing breast cancer have reported the
presence of increased amounts of the immunosuppressive
cytokine TGF-β1 in EVs released from cells resistant to
HER2-targeting drugs [107]. Although the patients’ cohort
was too small to be conclusive, these findings suggest that
the level of EVs-associated TGF-β1 in the plasma of the
patients correlates with resistance to Lapatinib and Tras-
tuzumab [107]. Resistance to apoptosis is a vital escape
mechanism by which tumor cells acquire drug resistance
and thus contribute to cancer progression. EVs-mediated
delivery of prosurvival factors is proposed to provide
tumor cells with an additional mechanism to suppress cell
death induced by anti-cancer drugs. Survivin is a prosurvi-
val protein member of the inhibitors of apoptosis (IAP)
family shown to be present in EVs derived from different
tumor types [108–110]. Survivin has been implicated in
the suppression of cell death and the regulation of mitosis,
and therapeutic strategies targeting survivin in cancer are
intensively investigated [111]. Indeed, Khan and colleagues
identified EVs as mediators of stress-induced survivin se-
cretion from HeLa cells treated with a sublethal dose of
proton irradiation [109]. More recently, Kreger and col-
leagues have reported that treating highly aggressive
MDA-MB-231 breast cancer cells with Paclitaxel
(PTX) induces the secretion of EVs enriched with sur-
vivin that significantly promote the survival of
serum-starved and PTX-treated fibroblasts and SKBR3
breast cancer cells [112].
Moreover, the enrichment of microRNAs (miR) in EVs
have been shown to promote anti-cancer drugs resistance
in different cancers (Table 1). For example, the investiga-
tion of drug resistance in breast cancer cells or pancreatic
ductal adenocarcinoma cells revealed that EVs-mediated
transfer of miR-155 to sensitive cells resulted in chemore-
sistance spreading. Interestingly, increased accumulation
of miRNA in EVs exposed to chemotherapeutic agents
can also serve as a disposal mechanism aimed at decreas-
ing the intracellular levels of miRNA with drug sensitivity
promoting roles [113, 114].
Tumor microenvironment-mediated intercellular
communication and drug resistance
Tumor growth and drug resistance are not only deter-
mined by cancer cells but are also supported by
non-tumor cells within the tumor microenvironment. The
importance of the role of EVs in the intercellular commu-
nication within the tumor microenvironment is increas-
ingly acknowledged. The bidirectional EV-mediated
transfer of cargo to and from non-tumor cells effectively
influences recipient cell’s phenotype as well as their
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response to anti-tumor treatments, thus promoting the
development of an environment hospitable towards cancer
growth, invasion, and metastasis. For instance, by secret-
ing chemoresistance-inducing EVs containing Snail and
miR-146, pancreatic cancer-associated fibroblasts (CAFs),
that are intrinsically resistant to the chemotherapeutic
agent gemcitabine, have been shown to mediate the trans-
fer of resistance to pancreatic cancer epithelial cells when
exposed to this drug, thereby increasing their proliferation
and survival [39]. Similarly, Binenbaum and colleagues
have recently reported that transfer of miR-365 in
macrophage-derived EVs induces resistance of pancreatic
adenocarcinoma cells to gemcitabine in vitro and in vivo
[115]. Moreover, CAF-derived EVs further promoted
tumor growth of colorectal cancer stem cells (CSCs) upon
treatment with 5-fluorouracil or oxaliplatin, even though
these cells were intrinsically chemoresistant. Interestingly,
the authors have also shown that inhibition of EVs secre-
tion by CAF increased chemosensitivity of colorectal CSCs
[116]. Likewise, the vesicular transfer of miR-21 from
cancer-associated adipocytes and fibroblasts to ovarian
cancer cells has been reported to decrease apoptosis and
promote chemoresistance to paclitaxel by downregulating
the expression of apoptotic peptidase activating factor
(APAF1) mRNA [117]. Similarly, tumor-associated macro-
phages (M2 polarized macrophages)-derived secretion of
miR-21 has been shown to confer cisplatin resistance in
gastric cancer cells. Functional studies revealed that ves-
icular miR-21 can be directly transferred from macro-
phages to gastric cancer cells, where it suppresses cell
apoptosis and enhances activation of PI3K/AKT signaling
pathway through down-regulation of PTEN [118]. Fur-
thermore, Boelens and colleagues have previously reported
that vesicular RNA from stromal cells, which are largely
noncoding transcripts and transposable elements, can be
transferred to breast cancer cells, leading to the expansion
of therapy and radiation resistant breast cancer cells
through a mechanism involving NOTCH3 induction
[119]. Accumulating pieces of evidence show that mesen-
chymal stem cells (MSCs) are chemo-attracted by tumors
where their plastic properties are reported to support
tumor growth. Indeed, human MSC-derived EVs were
Table 1 Extracellular vesicles miRNA cargo and chemoresistance in different cancers
Cancer Anti-cancer drugs Cell lines miRNA cargo Mechanism Reference
Lung Cisplatin A549/A549-DDP ↓ miR-100-5p horizontal transfer [133]
Lung Gemcitabine A549/A549-GR ↑ miR-222-3p horizontal transfer [134]
Lung Cisplatin A549/H1299 ↑ miR-96 horizontal transfer [135]
Lung Cisplatin A549/A549-DDP ↓ miR-146a-5p horizontal transfer [136]
Breast Docetaxel MCF-7 ↑ miR-100, miR-222, miR-30a, miR-17 horizontal transfer [137]




Hs578Ts ↓ miR-134 horizontal transfer [139]
Breast Doxorubicin
Paclitaxel




MDA-MB-231/HMLE ↑ miR-1246 horizontal transfer [141]
Breast Adriamycin MCF-7/MCF-7-Adr ↑ miR-222 horizontal transfer [142]
Oral cavity Cisplatin HSC-3/HSC-3R
SCC-9/SCC-9R






↑ miR-211–5p Autocrine [144]




↓ miR-34a horizontal transfer [146]
Colon Fluorouracil
(5-FU)
DLD-1/DLD-1-5-FU ↑ miR-145, miR-34a expulsion [113]
Pancreas Gemcitabine Panc1/Panc1-GR ↑ miR-155 horizontal transfer [147]
Leukemia Imatinib K562/K562-G01 ↑ miR-365 horizontal transfer [148]
Leukemia Daunorubicin HL60/HL60AR ↑ miR-196, miR20a expulsion [114]
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found to induce resistance of gastric cancer cells to
5-Fluorouracil both in vivo and ex vivo through the inhib-
ition of 5-fluorouracil-induced apoptosis and enhanced
expression of multidrug resistance-associated proteins.
The authors have reported that mesenchymal stem
cells-EVs could induce drug resistance in gastric cancer
cells by activating CaM-Ks/Raf/MEK/ERK signaling path-
way [120].
Cancer and stromal cells within the tumor microenvir-
onment have often restricted access to nutrients and
oxygen and thus are subjected to hypoxia [121]. In this
setting, hypoxia-induced EVs have been shown to con-
tribute to the chemoresistance of ovarian cancer cells in
a mechanism involving STAT3. Indeed, hypoxia-induced
EVs are capable of increasing the survival of tumor cells
in response to cisplatin treatment in vitro. In addition,
cisplatin efflux through EVs was shown to be signifi-
cantly augmented in ovarian cancer cell lines cultured
under hypoxic conditions [122].
The crosstalk between tumor cells and stromal cells is
bidirectional as cancer cells can also influence the be-
havior of stromal cells through EVs secretion. For in-
stance, Bandari and colleagues found that anti-myeloma
chemotherapy (Bortezomib, Carfilzomib, or Melphalan)
dramatically stimulates surface heparanase-rich EVs se-
cretion capable of degrading the ECM and that exposure
of these EVs to macrophages enhanced the secretion of
TNF-α (an important myeloma growth factor) and stim-
ulated their migration [123]. On the other hand,
anti-cancer drugs (Paclitaxel, etoposide, irinotecan
hydrochloride, or carboplatin) have been reported to
cause chemoresistant hepatocellular carcinoma cells to
release EVs that elicit superior anti-tumor NK cell re-
sponses compared to chemosensitive cells, in a mechan-
ism mediated by EV secretion of heat shock proteins.
Interestingly, this study provides a clue for finding an ef-
fective vaccine for hepatocellular carcinoma immuno-
therapy [124].
Strategies to mitigate EVs-mediated drug resistance
When considering strategies to mitigate the role of EVs
in transferring drug resistance, two major avenues come
to mind. The first one is to modulate the production of
EVs, by blocking their secretion. Because of the univer-
sality of EVs secretion and of the lack of drugs that can
specifically target secretion of EVs by cancer cells, this
strategy is likely to interfere with unwanted EVs secre-
tion, including the secretion of EVs involved with the ac-
quisition and transfer of resistance to anti-cancer drugs,
as well as with the secretion EVs involved in normal
physiological processes. The second possibility for miti-
gating drug resistance mediated by tumor-derived EVs is
to specifically remove these EVs once they have been
produced, without interfering with EVs secretion. This
approach has the advantage of maintaining the secretion
of “beneficial” EVs, affecting only those EVs secreted by
cancer cells. This second approach relies on the avail-
ability of markers specific for tumor-derived EVs. Such
markers are available for certain cancers. Both strategies
have been pursued in vitro and in vivo.
Federici et al. described the effect of proton pump in-
hibitor on both cisplatin uptake and EVs release in vitro
an in vivo in a mouse xenograft model of melanoma, in
which they show that treatment with a proton pump in-
hibitor decreases the overall EVs release and increases
tumor cell sensitivity to cisplatin [92]. Roseblade et al.
have evaluated the efficacy of several inhibitors of EVs
release in response to calcium mobilization, including
the use of a calpain inhibitor [125], which was also
shown to block EVs release by prostate cancer cell lines
in vitro and increased their sensitivity to chemotherapy
in vivo [126]. Similarly, Muralidharan-Chari et al.
showed that the inhibition of EVs release by preventing
the activation of the extracellular signal-regulated kinase
(ERK) using a MEK inhibitor, resulted in an increased
sensitivity of pancreatic cancer cell lines to gemcitabine
in vitro and in a tumor graft model in vivo [127]. While
the selectivity of agents specifically blocking EVs release
in cancer maybe lacking for most, some inhibitors target
isoforms of enzymes preferentially associated with
cancer cells. This is the case for inhibitors of peptidylar-
ginine deiminase PAD2 and PAD4 which are overex-
pressed in prostate, ovarian and other types of cancer
cells, and whose inhibition by chloramidine reduces the
release of EVs and increases cancer cell sensitivity to
drugs [128]. In a more systematic in vitro approach,
interference with different steps of EVs biogenesis in
prostate and breast cancer cell lines, Kosgodage et al.
confirmed that among a series of 11 inhibitors targeting
various steps of EVs biogenesis, PAD inhibitors, as well
as inhibitors of PKC (Bisindolylmaleimide-I), were the
most powerful inhibitors in prostate and breast cancer
cell lines [129]. Recently, the same group demonstrated
the powerful role of cannabinol (CBD) as an inhibitor of
EVs release by prostate, hepatocellular carcinoma, and
breast cancer cell lines, increasing cell sensitivity to
anti-cancer drugs [130].
While these pharmacologic interventions have proven
successful in vitro and in some cases in animal models
in vivo, their lack of selectivity for cancer cells, for the
most part, calls for some reservations on their systematic
therapeutic use. This is not the case for the specific re-
moval of circulating EVs from plasma. A method similar
to hemodialysis, extracorporeal hemofiltration using car-
tridges made of hollow fibers with a size cutoff of 200
nm coupled with an affinity matrix allows the specific
removal of ultrafiltrated EVs. This method, called
Adaptive Dialysis-like Affinity Platform Technology
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(ADAPT™), has been originally developed by Aethlon
Medical Inc. for removing Hepatitis C virus (HCV) par-
ticles from the blood of infected patients. The safety and
efficacy of the method have been clinically validated in
HCV infected end-stage renal disease patients using a
lectin as an affinity matrix for the selective removal of
HCV particles [131]. The extension of this method to
the specific removal of EVs with a size inferior to that of
the hollow fiber cutoff has been discussed by Marleau et
al. [132]. In a previous section, we discussed the involve-
ment of EVs in the escape to immunotherapies, by act-
ing as a sink for immuno-targeting drugs specific for
cancer-associated antigens such as CD20 in the case of
B cell lymphoma [85], HER2 in the case of breast cancer
[86] and more generally, PD-L1 [87, 88]. The specific re-
moval of EVs expressing these antigens by an appropri-
ate affinity hemofiltration device, such as those
described in the ADAPT™ method will likely mitigate
the immunotherapy sink effect mediated by EVs bearing
the targeted antigens.
Conclusions and future perspectives
Drug resistance is a huge hurdle in the treatment of can-
cer. Among the mechanisms governing the establish-
ment of resistance to anti-cancer therapies, EVs have
recently emerged as important modulators of drug re-
sistance through a variety of mechanisms described in
this review. EVs dynamically contribute, even though
transiently, to the heterogeneity of the tumor through
their diverse cargo content. Unraveling the precise bio-
logical composition of EVs will be critical to determining
their role in cancer and will likely aid in developing ther-
apies targeting these roles. However, the field still strug-
gles to assess EVs heterogeneity due to the lack of
standardized isolation techniques that go beyond subcel-
lular origin, size, and floatation density. Further dissec-
tion of EVs heterogeneity will be essential to improving
our understanding of the critical roles of EVs in cancer.
Exploiting EVs molecular cargo as well as the potential
development of EVs as drug vehicles for effective thera-
peutic strategies both hold promises in cancer diagnos-
tics and therapeutics. Omics on EVs derived from liquid
biopsies (such as blood, saliva or urine) will likely aid in
the early diagnosis of cancer through biomarkers discov-
ery or in the assessment of response to therapies while
avoiding invasive biopsy procedures. Related to thera-
peutics, EVs have been proposed as a new type of drug
delivery system. Bioengineered EVs loaded with chemo-
therapeutic drugs or expressing ligands which target par-
ticular malignant cells have the potential for future
cancer treatment. The inherent protection of the cargo
and personalized cellular targeting simultaneously en-
hance the solubility, stability, and specificity of the thera-
peutic agent.
Given the prominence of EVs in almost all aspects of
tumor development and progression, it seems evident to
explore translational approaches that would prevent
these undesirable effects. Nevertheless, EVs-mediated
cell-to-cell communication is a conserved mechanism in
normal cell physiology and their inhibition is likely to be
toxic unless specific strategies distinguishing pathogenic
EVs from beneficial ones are developed. In order to de-
velop such strategies, it is essential to establish standard-
ized techniques allowing consistent isolation of EVs
subpopulations. This knowledge is necessary to identify
cancer-derived EVs that should be targeted by any thera-
peutic approach. The use of EVs as cell-free therapies
has also been employed in cancer vaccine and immuno-
therapy fields. Encouraging studies suggest the use of
immune cells-derived EVs as a new potential strategy for
cancer vaccine research. Only if taken together, technol-
ogy and biology will pave the way for the future use of
EVs in many clinical applications.
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